
Lindsay Bealor Greenleaf, head of Federal and State Policy at ADVI Health, talks with Managed Healthcare Executive about Robert F. Kennedy Jr., President Donald Trump’s HHS secretary nominee.

A panelist discusses how she navigates the economic challenges of neurokinin-targeted therapies by working with insurance providers and patient assistance programs while advocating for expanded access among underserved populations who may particularly benefit from these treatment options.

Potential threats to HIV care and fallout over the next four years, according to Jose Abrigo, Esq., HIV project director at Lambda Legal Defense and Education Fund and Carl Schmid, executive director of the HIV+Hepatitis Policy Institute.

A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while prioritizing operational efficiency, patient access, and seamless transitions between reference products and biosimilars.

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved, exploring how they could address key unmet needs, improve patient outcomes, and optimize healthcare resource utilization.

Panelists provide an overview of emerging therapies for progressive pulmonary fibrosis (PPF), highlighting the latest developments and potential treatment options.

Panelists discuss the key gaps and unmet needs in current management strategies for progressive pulmonary fibrosis (PPF) and how ongoing research and collaborative efforts may help address these challenges.

A panelist discusses how she proactively addresses safety concerns about neurokinin-targeted therapies through evidence-based patient education and systematic monitoring while implementing streamlined protocols and documentation systems to effectively integrate these treatments into clinical workflow.

A panelist discusses how she carefully transitions patients to neurokinin-targeted therapies by establishing realistic timelines for symptom improvement and actively monitoring patient response while providing education about potential benefits and limitations of the new treatment approach.